PDE4B inhibitor is an inhibitor of phosphodiesterase 4B (PDE4B; IC50 = 140 nM).1,2 It is selective for PDE4B over a panel of 20 PDE isoforms and a panel of 39 CNS receptors at 10 μM but does inhibit the activity of PDE4C1, PDE3B, the serotonin (5-HT) receptor subtype 5-HT2C, and sigma-2 (σ2) receptors by greater than 50%.1 PDE4B inhibitor (1 μM) decreases LPS- or Pam3Cys-induced production of TNF-α in mouse bone marrow-derived macrophages (BMDMs). It reduces cocaine self-administration and the progressive ratio breakpoint in mice when administered at a dose of 5 mg/kg.2
1.Vadukoot, A.K., Sharma, S., Aretz, C.D., et al.Synthesis and SAR studies of 1H-pyrrolo[2,3-b]pyridine-2-carboxamides as phosphodiesterase 4B (PDE4B) inhibitorsACS Med. Chem. Lett.11(10)1848-1854(2020)
2.Burkovetskaya, M.E., Liu, Q., Vadukoot, A.K., et al.KVA-D-88, a novel preferable phosphodiesterase 4B inhibitor, decreases cocaine-mediated reward properties in vivoACS Chem. Neurosci.11(15)2231-2242(2020)
